Chairman Genclis SAS.
Bernard Bihain graduated as MD from the Free University of Brussels (ULB) in 1985 and has over 20 years of experience in scientific research.
His background encompasses:
- the discovery of the second apo BE lipoprotein receptor, a major molecular link between obesity hyper-lipoproteinemia and possibly cancer, today confirmed by an independent research group;
- the discovery of Famoxin, the lead therapeutic protein of Genset;
- the discovery of a novel method for peanut allergy diagnosis, which was licensed to the leader in the allergy diagnostics sector and has led to disensitisation of over ten children in France during the early part of 2009; and
- the discovery that transcription infidelity (TI) is increased in cancer and the application of TI to early stage breast, lung, colon and prostate cancer detection with respective marketing authorisations in Europe expected from 2009 to end 2010.
- Before joining Genclis in 2004, which later became a subsidiary of Transmedi, Bernard had an academic and biotech start-up background, both in France and the US. This included:
- Fellowship at Columbia University;
- Assistant Professor at Louisiana State University;
- Director of Research at INSERM
- Director of INSERM U391;
- Chairman of the Department of Biochemistry, Faculty of Pharmacy, University of Rennes;
- Vice president of functional genomics at Genset, San Diego;
- Chief Scientific Officer, Valigen, New York.